Skip to main content
Premium Trial:

Request an Annual Quote

BGI and Diagenode To Co-Develop Standardization Methods for Epigenetics Sample-Prep for NGS

Premium

BGI and Diagenode will collaborate to develop standard methods in sample prep for next-generation sequencing for epigenetics research, the companies said today.

Under the deal, Diagenode will provide BGI with early access to its developments in chromatin- and DNA methylation-analysis methods and tools. The company is aiming to "increase the consistency and precision" of its epigenetic sample-prep assays for next-gen sequencing, including its ChIP, MeDIP, methyl-CpG biding domain protein capture, bisulfite conversion, and DNA fragmentation assays.

BGI has been using Diagenode's reagents and its Bioruptors, which shear DNA and chromatin, for epigenetics research and exon sequencing, according to BGI officials.

"Consistency is extremely important, not only for saving reagents and precious samples, but also for creating universal high standards in the emerging field of epigenetics," Diagenode's CEO Didier Allaer, said in a statement.

Financial terms of the deal were not disclosed.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.